The relevant information included in this section is exactly as published on the website of the National Securities Market Commission (CNMV)
Filter results
| Date | Title | Content | |
|---|---|---|---|
| 5/07/2019 | R&D: new licenses, patents and registered trademarks | ROVI announces completion of the Clinical Trial Program that will support the application for marketing authorization for Doria® for the treatment of schizophrenia. | |
| 2/07/2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the second quarter of 2019 | |
| 26/06/2019 | Información sobre dividendos | The Company informs about the dividends payment | |
| 12/06/2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | |
| 8/05/2019 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its 2019 General Shareholders Meeting | |
| 8/05/2019 | Information on P&L | ROVI releases the press release related to the first quarter 2019 financial results | |
| 8/05/2019 | Information on P&L | ROVI releases the first quarter 2019 results presentation | |
| 7/05/2019 | Liquidity contracts and specialists | ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A. | |
| 30/04/2019 | Liquidity contracts and specialists | ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U. | |
| 11/04/2019 | Strategic agreements with third parties | The Company releases the press release related to the marketing agreement of Tetridar® in Spain |